Amendments to the Specification:

Please add, at page 1, between lines 1 and 5, the following new section:

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation of U.S. Patent Application No. 09/920,454, filed August 08, 2001, now allowed; which application is a continuation of U.S. Patent Application No. 08/788,339, filed January 27, 1997, which issued as U.S. Patent No. 6,287,536; which application is a divisional of U.S. Patent Application No. 08/122,979, filed September 16, 1993, which issued as U.S. Patent No. 5,630,996; which application is a continuation of International Application No. PCT/US93/05406, filed June 7, 1993, designating the United States; which application is a continuation-in-part of U.S. Patent Application No. 07/995,381, filed December 23, 1992, abandoned; which application is a continuation in part of U.S. Patent Application No. 07/895,588, filed June 9, 1992, which issued as U.S. Patent No. 5,283,342; all of which applications are incorporated herewith in their entirety and to which priority is claimed.

Please insert, beginning at page 5, between lines 25 and 27, the following two new paragraphs:

Figure 19 illustrates a typical pretargeting approach.

Figure 20 illustrates a pretargeting protocol for a monoclonal antibody-zinc finger protein and double stranded (ds) DNA-therapeutic agent.

At page 11, line 10, please amend the paragraph to read as follows:

A typical pretargeting approach ("three-step") is schematically depicted ~~below~~ in Figure 19.

At page 11, please delete line 12 to the bottom of the page (which is the depiction that is now found in Figure 19).

At page 28, line 14, please amend the paragraph to read as follows:

A schematic of the administered components and ultimate in vivo formed "sandwich" for a monoclonal antibody-zinc finger protein/dsDNA-therapeutic agent two-step pretargeting protocol ~~are shown below~~ is depicted in Figure 20.

At page 28, please delete the diagram beginning at line 19, to page 29 line l, (which is the depiction that is now found in Figure 20).